[1]张健俊１ 刘文洲２ 欧莉３.红杏丸治疗高脂血症临床研究 及其对 ＴＮＦ－ɑ、ＩＬ－６、ＥＴ－１的影响[J].现代中医药,2019,(02):096-100.[doi:10.13424/j.cnki.mtcm.2019.02.029]
　Zhang Jianjun Liu Wenzhou Ou Li.Clinical Study on Treatment of Hyperlipidemia with Hongxing Pill and Its Effects on TNF - ɑ, IL -6 and ET -1[J].Modern Traditional Chinese Medicine,2019,(02):096-100.[doi:10.13424/j.cnki.mtcm.2019.02.029]
点击复制

红杏丸治疗高脂血症临床研究 及其对 ＴＮＦ－ɑ、ＩＬ－６、ＥＴ－１的影响 ()
分享到：

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2019年02期
页码:
096-100
栏目:
方药研究
出版日期:
2019-03-10

文章信息/Info

Title:
Clinical Study on Treatment of Hyperlipidemia with Hongxing Pill and Its Effects on TNF - ɑ, IL -6 and ET -1
文章编号:
1672-0571(2019)02-0096-05
作者:
张健俊１ 刘文洲２ 欧莉３
重１．咸阳市城投医疗集团风轮医院，陕西 咸阳 ７１２０００；２．西电集团医院，陕西 西安 ７１００７７； ３．陕西中医药大学，陕西 咸阳 ７１２０４６
Author(s):
Zhang Jianjun 1 Liu Wenzhou 2 Ou Li 3
1. Fenglun Hospital of Xianyang City Investment Medical Group, Xianyang China, 712000; 2. Xi'an XD Group Hospital, Xi’ an China, 710007; 3. Shaanxi University of Chinese Medicine, Xianyang China, 712046
关键词:
红杏丸; 高脂血症; 临床研究; 血管内皮功能
Keywords:
Hongxing Pill;  hyperlipemia;  clinical study;  vascular endothelial function
分类号:
R589.2
DOI:
10.13424/j.cnki.mtcm.2019.02.029
文献标志码:
A
摘要:
摘 要：目的 探讨红杏丸治疗高脂血症的临床疗效及其对肿瘤坏死因子（ＴＮＦ－ɑ）、白介素 －６（ＩＬ－６）、内 皮素 －１（ＥＴ－１）指标的影响。方法 采用随机、双盲、平行对照的试验设计方法，将纳入我院 ２０１７年 ９月 ～１０ 月的 １１２例高脂血症患者按照 １：１的比例进行随机分组，治疗组与对照组各 ５６例，其中治疗组给予红杏丸，对 照组给予安慰剂，疗程 ６０天。在试验过程中，治疗组脱落 ４例，对照组脱落 ５例，最终进入统计分析的例数，治 疗组 ５２例，对照组 ５１例。试验结束揭盲后，分析红杏丸治疗高血
Abstract:
To explore the clinical efficacy of Hongxing Pill in the treatment of hyperlipidemia and its effects on tumor necrosis factor ( TNF - ɑ) , interleukin -6 ( IL -6) and endothelin -1 ( ET -1) . Method A randomized, double - blind, parallel - controlled trial design method was used to randomize 112 patients with hyperlipidemia who were included in our hospital from September to October 2017 according to a 1: 1 ratio. The treatment group and the control group each had 56 cases. The treatment group was given Hongxing Pills, and the control group was given a placebo for 60 days. In the course of the experiment, there were 4 cases failed in the treatment group and 5 cases in the control group. Finally, there were 52 cases in the treatment group and 51 cases in the control group. After the blindness was uncovered, the therapeutic effect of Hongxing Pill on hyperlipidemia and its influence on TNF - _, IL -6 and ET -1 were analyzed. Result The effective rates of total cholesterol, triglyceride and high density lipoprotein in the treatment group were 59. 62%, 55. 77% and 51. 92%, significantly higher than those in the placebo control group ( 9. 80%, 3. 92% and 19. 61%) . TC and TG values in the treatment group were significantly lower than those in the control group, while HDL- C value was significantly higher than that in the control group. ET -1 and inflammatory factors TNF - _and IL -6 were lower than those in the placebo control group, with statistical significance. Conclusion Hongxing Pill can not only effectively regulate the blood lipid level of patients with hyperlipidemia, but also protect vascular endothelial function and improve inflammation by reducing TNF - _, IL -6 and ET -1.

参考文献/References:

[1]孙芳,尚文斌.中医药治疗高脂血症的研究进展[J].中医药信息,2011,28(2):120-123.
[2]晓勇.高血脂症的危害及预防[N].健康报,2002-06-04(004).
[3]黄震华,徐济民.高脂血症治疗进展[J].上海预防医学,2003,15(5):210-213.
[4]王晓书,唐媛媛,孙易红.血府逐瘀胶囊治疗气滞血瘀型高脂血症的临床研究[J].中药药理与临床,2017,33(5):177-180.
[5]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志,2007;19(5):390-419.
[6]唐娟,王德芳,徐艳,等.缺血后处理对高脂血症大鼠脑缺血再灌注后脑组织TNF-ɑ和SOCS-3表达的影响[J].山东医药,2016,56(37):38-40.
[7]周子严,薛晓琳,李鑫,等.从痰瘀论治血脂异常的文献研究[J].中华中医药杂志,2018,33(4):1485-1488.
[8]陈富荣,章怡,刘萍.痰瘀互结型高脂血症主要中医症状的分布特点[J].中华中医药学刊,2009,27(12):2508-2510.
[9]赵水平.调脂药物概述[J].中南药学,2011,9(1):68-71.
[10]袁文姬.合用他汀类药物不良反应的分析[J].中国医药导报,2011,8(3):119,121.
[11]赵水平.烟酸类调脂药物研究进展[J].临床药物治疗杂志,2010,8(2):5-8.
[12]吴文静,柯元南,郑金刚.新型降脂药-依折麦布的研究进展[J].心血管病学进展,2009,30(4):558-561.
[13]张惠芳,黄之训.功能红曲生理活性作用机制和治疗保健功效[J].中华医学与健康,2007,4(2):77-79.
[14]刘杰,张燕,鲍进方,等.脂必妥治疗飞行员高血脂症的临床研究[J].中国疗养医学,2008,17(5):310-311.
[15]温学伟,马新,周立平,等.红曲抗氧化的研究进展[J].食品工业科技,2011,32(2):376-378.
[16]吴沁.银杏叶调节血脂和抗氧化作用研究[J].江苏预防医学,2010,21(6):10-12.
[17]何星篧,刘臖,罗春,等.银杏叶治疗高脂血症的网络药理学研究[J].中国医院药学杂志,2016,36(10):787-791.
[18] Adibhatla RM, Hatcher JF. Secretory phospholipase A2 ⅡA is up - regulated by TNF - ɑ and IL -1ɑ/ βafter transient focal cerebral is - chemia in rat[ J] . Brain Res,2007,1134( 1) :199 -205.
[19] Boyle K, Zhang J, Nicholson S, et al. Deletion of the SOCS box of suppressor of cytokine signaling 3 ( SOCS3) in embryonic stemcells reveals SOCS box - dependent regulation of JAK but not STAT phosphorylation [ J] . Cell Sign,2009,21( 3) :394 -404.
[20]熊伟平,边长勇.瑞舒伐他汀治疗冠心病伴高脂血症的疗效及其对血脂炎性介质及内皮指标的影响[J].山西医药杂志,2017,46(23):2909-2911.

相似文献/References:

[1]许虎军１,阮家安２,高峰３,等.沙藤红曲软胶囊治疗高脂血症的临床研究[J].现代中医药,2019,(05):061.[doi:10.13424/j.cnki.mtcm.2019.05.019]
　Xu Hujun Ruan Jia an Gao Feng Li Min.Clinical Study on Treatment of Hyperlipidemia with Shateng Hongqu Soft Capsule[J].Modern Traditional Chinese Medicine,2019,(02):061.[doi:10.13424/j.cnki.mtcm.2019.05.019]
[2]何 平.五脏论治高脂血症的理论及经验总结[J].现代中医药,2020,(01):027.[doi:10.13424/j.cnki.mtcm.2020.01.007]
[3]刘睿位佳琳位鸿 尚坤 何蕊 陈少波 汪景 杨戈.泽明降脂颗粒制备工艺的优化及 质量标准研究[J].现代中医药,2022,1(05):033.[doi:10.13424/j.cnki.mtcm.2022.05.006]
[4]杨洋刘昳张哲郑清莲刘艳张莹李帅.郑清莲教授应用三仁汤加减治疗高脂血症经验[J].现代中医药,2024,(01):020.[doi:10.13424/j.cnki.mtcm.2024.01.005]
　YANG YangLIU YiZHANG ZheZHENG QinglianLIU YanZHANG YingLI Shuai.Professor ZHENG Qinglians Experience in TreatingHyperlipidemia with Modified SanrenDecoction for Tongli Sanjiao[J].Modern Traditional Chinese Medicine,2024,(02):020.[doi:10.13424/j.cnki.mtcm.2024.01.005]

备注/Memo

备注/Memo:
基金项目：陕西省秦岭中草药应用开发工程技术研究中心项目（２００８ＺＤＧＣ－３２）
更新日期/Last Update: 2019-03-15